Bivalirudin in patients with Heparin-Induced Thrombocytopenia undergoing Percutaneous Coronary Intervention

Journal of Invasive Cardiology

Volumn 12, Issue SUPPL. F, 2000, Pages

  Campbell, Kevin R ^a   Mahaffey, Kenneth W ^a   Lewis, Bruce E ^b   Weitz, Jeffrey I ^c   Berkowitz, Scott D ^a   Ohman, E Magnus ^a   Califf, Robert M ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; DRUG DERIVATIVE; HEPARIN; HIRUDIN DERIVATIVE; HIRULOG; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN;

ANGINA PECTORIS; ANTICOAGULANT THERAPY; CHEMICALLY INDUCED DISORDER; CORONARY ARTERY THROMBOSIS; HUMAN; METHODOLOGY; REVIEW; SAFETY; THROMBOCYTOPENIA; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ANGINA PECTORIS; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; ANTITHROMBINS; CORONARY THROMBOSIS; HEPARIN; HIRUDIN THERAPY; HIRUDINS; HUMANS; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; SAFETY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0034575814     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Warkentin TE, Levin MN, Hirsh J. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J of Med 1995;332:1330-1335.
2. Singer RL, Mannion JD, Bauer TL, et al. Complications from heparin induced thrombocytopenia in patients undergoing cardiopulmonary bypass. Chest 1993;104:1436-1440.
3. Ortel TL. Heparin-induced thrombocytopenia. Semin Hematology 1998;35(Suppl 5):1-2.
4. Chong BH, Eisbacher M. Pathophysiology and laboratory testing of heparin-induced thrombocytopenia. Semin Hematology 1998;35(Suppl 5):3-8.
5. Warkentin TE. Clinical presentation of heparin-induced thrombocytopenia. Semin Hematology 1998;35(Suppl 5):9-16.
6. Amiral J. Antigens involved in heparin-induced thrombocytopenia. Semin Hematology 1999;36(Suppl 1):7-11.
7. Kaplan KL, Francis CW. Heparin-induced thrombocytopenia. Thromb Haemost 1999;13:1-7.
8. Aster R. Drug-induced thrombocytopenia: An overview of pathogenesis. Semin Hematology 1999;36(Suppl):2-5.
9. Raible MD. Hematologic complications of heparin-induced thrombocytopenia. Semin Thromb Hemost 1999;25(Suppl):17-21.
10. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996;101:502-507.
11. Kelton JG. The clinical management of heparin-induced thrombocytopenia. Semin Hematology 1999;36(Suppl 1):17-21.
12. Warkentin TE. Heparin-induced thrombocytopenia: Pathogenesis, frequency, avoidance and management. Drug Safety 1997;5:325-341.
13. Walenga JM, Jeske WP, Wood JJ, et al. Laboratory tests for heparin-induced thrombocytopenia: A multicenter study. Semin Hematology 1999;36(Suppl 1):22-28.
14. Walenga JM, Jeske WP, Fasanella AR, et al. Laboratory tests for the diagnosis of heparin-induced thrombocytopenia. Semin Thrombosis and Hemostasis 1999;25(Suppl 1):43-49.
15. Wallis DE, Workman DL, Lewis BE, et al. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 1999;106:629-635.
16. Warkentin TE. Limitations of conventional treatment options for heparin-induced thrombocytopenia. Semin Hematology 1998;35(Suppl 5):17-25.
17. Horellou MH, Conrad J, Lecrubier C, et al. Persistent heparin induced thrombocytopenia despite therapy with low-molecular-weight heparin. Thromb Haemost 1984;51:134.
18. Leroy J, Leclerc MH, Delahousse B, et al. Treatment of heparin associated thrombocytopenia and thrombosis with low-molecular-weight heparin (CY 216) Semin Thromb Hemost 1985;11:326-329.
19. Chong BH, Ismail F, Cade J, et al. Heparin induced thrombocytopenia: Studies with new low-molecular-weight heparinoid Org 10172. Blood 1989;73:1592-1596.
20. Hale LP, Smith K, Braden GA, Owen J. Orgaran during rotational atherectomy in the setting of heparin-induced thrombocytopenia. Cathet Cardiovasc Diagn 1998;45:318-322.
21. Cantor WJ, Leblanc K, Garvey B, et al. Combined use of Orgaran and Reopro during coronary angioplasty in patients unable to receive heparin. Cathet Cardiovasc Intervent 1999;46:352-355.
22. Hursting MJ, Alford KL, Becker JP, et al. Novastan (brand of argatroban): A small molecule, direct thrombin inhibitor. Semin Thromb Hemost 1997;23:503-516.
23. Lewis BE, Walenga JM, Wallis DE. Anticoagulation with Novastan (argatroban) in patients with heparin induced thrombocytopenia and thrombus syndrome. Seminars in Thrombosis and Hemostasis. 1997;23:197-202.
24. Stringer KA, Lindenfield J. Hirudins: Antithrombin anticoagulants. Ann Pharmacotherapy 1992;26:1535-1540.
25. Greinacher A, Volpel H, Janssens U, et al., for the HAT investigators group. Recombinant hirudin (lepirudin) provides effective and safe anticoagulation in patients with heparin-induced thrombocytopenia type II: A prospective study. Circulation 1999;99:73-80.
26. Greinacher A, Janssens U, Berg G, et al., for the HAT investigators group. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 1999;100:587-593.
27. Matthai WH. Use of argatroban during percutaneous coronary interventions in patients with heparin-induced thrombocytopenia. Semin Thromb Hemost 1999;25(Suppl 1):57-60.
28. Lewis BE, Matthai W, Grassman ED, et al. Results of phase 2/3 trial of argatroban anticoagulation during PTCA of patients with heparin induced thrombocytopenia. Circulation 1997;96:I-217.
29. Lewis BE, Ferguson JS, Grassman ED, et al. Successful coronary interventions performed with argatroban in patients with heparin induced thrombocytopenia and thrombosis syndrome. J Invas Cardiol 1996;8:410-417.
30. Greinacher A, Volpel H, Potzsch B. Recombinant hirudin in the treatment of patients with heparin induced thrombocytopenia (Abstr). Blood 1996;88(Suppl A):281A.
31. Schiele G, Vuillnenot A, Kramarz P, et al. Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia. Am J Hematol 1995;50:20-25.
32. Topol EJ, Bonan R, Jewitt D, et al. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 1993;87:1622-1629.
33. Bittl JA, Strony J, Brinker JA, et al., for the Hirulog Angioplasty Study investigators. Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or post-infarction angina. N Engl J Med 1995;333:764-769.